|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
11-deoxyprostaglandin E1 inhibits the reaction [Ibuprofen results in decreased expression of NOS3 mRNA] |
CTD |
PMID:10525081 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions increases expression |
EXP |
16,16-Dimethylprostaglandin E2 inhibits the reaction [Ibuprofen results in decreased expression of NOS3 mRNA] 16,16-Dimethylprostaglandin E2 results in increased expression of NOS3 mRNA |
CTD |
PMID:10525081 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
[15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid co-treated with EDN1 protein] results in decreased chemical synthesis of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:16325014 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
|
G |
HSD3B1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
EXP |
Cloprostenol results in increased expression of HSD3B1 mRNA |
CTD |
PMID:15713365 |
|
NCBI chr 4:101,565,229...101,574,110
|
|
G |
LDLR |
low density lipoprotein receptor |
decreases expression |
EXP |
Cloprostenol results in decreased expression of LDLR mRNA |
CTD |
PMID:15713365 |
|
NCBI chr 2:69,828,348...69,864,823
Ensembl chr 2:69,828,332...69,864,827
|
|
G |
LHCGR |
luteinizing hormone/choriogonadotropin receptor |
decreases expression |
EXP |
Cloprostenol results in decreased expression of LHCGR mRNA; Cloprostenol results in decreased expression of LHCGR protein |
CTD |
PMID:15713365 |
|
NCBI chr 3:91,964,415...92,023,821
Ensembl chr 3:91,964,415...92,021,398
|
|
G |
NR0B1 |
nuclear receptor subfamily 0 group B member 1 |
increases expression |
EXP |
Cloprostenol results in increased expression of NR0B1 mRNA |
CTD |
PMID:15713365 |
|
NCBI chr X:26,117,874...26,122,951
Ensembl chr X:26,117,874...26,122,951
|
|
G |
STAR |
steroidogenic acute regulatory protein |
decreases expression |
EXP |
Cloprostenol results in decreased expression of STAR mRNA; Cloprostenol results in decreased expression of STAR protein |
CTD |
PMID:15713365 |
|
NCBI chr15:48,377,597...48,385,398
Ensembl chr15:48,377,521...48,385,462
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions increases expression |
EXP |
BW A868C inhibits the reaction [Prostaglandin D2 results in increased expression of NOS3 mRNA]; Prostaglandin D2 inhibits the reaction [BW A868C results in decreased expression of NOS3 mRNA] |
CTD |
PMID:10644584 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
[15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid co-treated with EDN1 protein] results in decreased chemical synthesis of Dinoprostone |
CTD |
PMID:16325014 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
G |
OXT |
oxytocin/neurophysin I prepropeptide |
increases abundance multiple interactions increases secretion |
EXP |
OXT protein results in increased abundance of Dinoprostone Progesterone inhibits the reaction [OXT protein results in increased secretion of Dinoprostone] |
CTD |
PMID:16997130 PMID:21370738 |
|
NCBI chr17:32,605,586...32,606,449
Ensembl chr17:32,605,586...32,606,546
|
|
G |
PLA2G1B |
phospholipase A2 group IB |
increases chemical synthesis |
EXP |
PLA2G1B protein results in increased chemical synthesis of Dinoprostone |
CTD |
PMID:10706128 |
|
NCBI chr14:40,314,520...40,322,315
Ensembl chr14:40,314,520...40,322,315
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[Polychlorinated Biphenyls results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; alpha-Linolenic Acid inhibits the reaction [[Polychlorinated Biphenyls results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Linoleic Acid promotes the reaction [[Polychlorinated Biphenyls results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Polychlorinated Biphenyls promotes the reaction [[Linoleic Acid results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone] |
CTD |
PMID:18155686 PMID:20825639 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
|
G |
CASP3 |
caspase 3 |
increases activity multiple interactions increases expression |
EXP |
Dinoprost results in increased activity of CASP3 protein [epostane co-treated with Dinoprost] results in increased activity of CASP3 protein; Dinoprost promotes the reaction [epostane results in increased expression of CASP3 mRNA]; epostane promotes the reaction [Dinoprost results in increased expression of CASP3 mRNA] |
CTD |
PMID:20739670 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
increases expression multiple interactions |
EXP |
Dinoprost results in increased expression of CCL2 mRNA [Dinoprost co-treated with epostane] results in increased expression of CCL2 mRNA |
CTD |
PMID:21505051 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CCL4 |
C-C motif chemokine ligand 4 |
increases expression multiple interactions |
EXP |
Dinoprost results in increased expression of CCL4 mRNA [Dinoprost co-treated with epostane] results in increased expression of CCL4 mRNA |
CTD |
PMID:21505051 |
|
NCBI chr12:39,479,190...39,480,511
Ensembl chr12:39,478,882...39,481,082
|
|
G |
CCL8 |
chemokine (C-C motif) ligand 8 |
increases expression multiple interactions |
EXP |
Dinoprost results in increased expression of CCL8 mRNA [Dinoprost co-treated with epostane] results in increased expression of CCL8 mRNA |
CTD |
PMID:21505051 |
|
NCBI chr12:40,740,468...40,741,970
Ensembl chr12:40,740,023...40,742,022
|
|
G |
CCR1 |
C-C motif chemokine receptor 1 |
multiple interactions increases expression |
EXP |
epostane promotes the reaction [Dinoprost results in increased expression of CCR1 mRNA] |
CTD |
PMID:21505051 |
|
NCBI chr13:29,227,218...29,233,862
Ensembl chr13:29,227,222...29,233,960
|
|
G |
CCR2 |
C-C motif chemokine receptor 2 |
increases expression multiple interactions |
EXP |
Dinoprost results in increased expression of CCR2 mRNA epostane promotes the reaction [Dinoprost results in increased expression of CCR2 mRNA] |
CTD |
PMID:21505051 |
|
NCBI chr13:29,368,735...29,374,564
Ensembl chr13:29,285,012...29,376,343
|
|
G |
CCR5 |
C-C motif chemokine receptor 5 |
increases expression multiple interactions |
EXP |
Dinoprost results in increased expression of CCR5 mRNA epostane promotes the reaction [Dinoprost results in increased expression of CCR5 mRNA] |
CTD |
PMID:21505051 |
|
NCBI chr13:29,382,383...29,387,902
Ensembl chr13:29,383,303...29,387,895
|
|
G |
CXCL2 |
chemokine (C-X-C motif) ligand 2 |
multiple interactions increases expression |
EXP |
[Dinoprost co-treated with epostane] results in increased expression of CXCL2 mRNA Dinoprost results in increased expression of CXCL2 mRNA |
CTD |
PMID:21505051 |
|
NCBI chr 8:70,157,253...70,159,145
Ensembl chr 8:70,157,214...70,159,138
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
increases expression multiple interactions |
EXP |
Dinoprost results in increased expression of CXCL8 mRNA [Dinoprost co-treated with epostane] results in increased expression of CXCL8 mRNA |
CTD |
PMID:21505051 |
|
NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
|
|
G |
CXCR2 |
C-X-C motif chemokine receptor 2 |
multiple interactions increases expression |
EXP |
epostane promotes the reaction [Dinoprost results in increased expression of CXCR2 mRNA] |
CTD |
PMID:21505051 |
|
NCBI chr15:120,219,657...120,230,203
|
|
G |
CYP19A3 |
cytochrome P450 19A3 |
multiple interactions |
EXP |
[epostane co-treated with Dinoprost] results in increased expression of CYP19A1 mRNA |
CTD |
PMID:20739670 |
|
NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899
|
|
G |
GHRL |
ghrelin and obestatin prepropeptide |
increases secretion multiple interactions |
EXP |
GHRL protein results in increased secretion of Dinoprost STAT1 protein inhibits the reaction [GHRL protein results in increased secretion of Dinoprost] |
CTD |
PMID:19528263 |
|
NCBI chr13:66,442,106...66,453,576
Ensembl chr13:66,445,992...66,452,917
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
increases phosphorylation |
EXP |
Dinoprost results in increased phosphorylation of NFKBIA protein |
CTD |
PMID:21505051 |
|
NCBI chr 7:64,508,119...64,510,754
Ensembl chr 7:64,507,822...64,511,277
|
|
G |
OXT |
oxytocin/neurophysin I prepropeptide |
multiple interactions increases abundance increases secretion |
EXP |
Progesterone inhibits the reaction [OXT protein results in increased abundance of Dinoprost]; Progesterone inhibits the reaction [OXT protein results in increased secretion of Dinoprost] |
CTD |
PMID:16997130 PMID:21370738 |
|
NCBI chr17:32,605,586...32,606,449
Ensembl chr17:32,605,586...32,606,546
|
|
G |
PLA2G1B |
phospholipase A2 group IB |
multiple interactions |
EXP |
[epostane co-treated with Dinoprost] results in increased expression of PLA2G1B mRNA |
CTD |
PMID:20739670 |
|
NCBI chr14:40,314,520...40,322,315
Ensembl chr14:40,314,520...40,322,315
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[epostane co-treated with Dinoprost] results in increased expression of PTGS2 mRNA |
CTD |
PMID:20739670 |
|
NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
|
|
G |
STAT1 |
signal transducer and activator of transcription 1 |
multiple interactions increases secretion |
EXP |
STAT1 protein inhibits the reaction [GHRL protein results in increased secretion of Dinoprost] STAT1 protein results in increased secretion of Dinoprost |
CTD |
PMID:19528263 |
|
NCBI chr15:95,593,201...95,646,324
Ensembl chr15:95,593,211...95,646,260
|
|
|
G |
CYP17A1 |
cytochrome P450 family 17 subfamily A member 1 |
multiple interactions |
EXP |
9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:11889176 |
|
NCBI chr14:113,805,616...113,820,445
Ensembl chr14:113,805,611...113,812,041
|
|
G |
INS |
insulin |
multiple interactions |
EXP |
9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione]; 9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone]; 9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:11889176 |
|
NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
|
|
G |
LHB |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione]; 9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone]; 9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [[LHB protein co-treated with INS protein] results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:11889176 |
|
NCBI chr 6:54,263,574...54,269,286
Ensembl chr 6:54,263,576...54,271,086
|
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
sulprostone inhibits the reaction [Ibuprofen results in decreased expression of NOS3 mRNA] |
CTD |
PMID:10525081 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|